Market Overview

Amazon Breaks Walgreens' Bullish Cycle, More Downside To Come

Share:
Amazon Breaks Walgreens' Bullish Cycle, More Downside To Come

After recently joining the Dow Jones blue chip index, Walgreens Boots Alliance Inc (NASDAQ: WBA) began the day on a high note, reporting earnings per share of $1.35 and total revenue of $34.33 billion, above analyst expectations of $1.08 and $34.05 billion. Walgreens also announced a dividend hike and $10 billion in stock buybacks. Despite concerns about same store sales figures, Walgreens was trading 2.5% higher in premarket trading.

Then Amazon.com, Inc. (NASDAQ: AMZN) announced that it had agreed to buy a privately held online pharmacy called PillPack. Walgreens fell over 12 percent from its premarket high and other pharmacies such as CVS Health Corp (NYSE: CVS) and Rite Aid Corporation (NYSE: RAD) fell around 10 percent as well. This is not unprecedented after Amazon decides to enter a new market, known as “Amazon effect”. Even the SPDR S&P Pharmaceuticals ETF (NYSE: XPH) was down 1 percent.

In analyzing the Walgreens weekly chart, we can see that it was trading in its rising phase, fairly early in the current market cycle. However, it has now broken below its cycle low, which is a bearish indicator for the price action remaining in this cycle. Further, the stock has been in poor technical condition, recently failing from resistance. In January, we added it to our "Riskiest of 2018" list. With so much time left in this cycle, our current target is $51 by mid-September.

Walgreens Boots Alliance Stock Chart with Weekly Bars

For more from Slim or to learn about cycle analysis, check out the askSlim Market Week show every Friday on our YouTube channel.

Related Links:

Amazon To Buy Online Pharmacy PillPack; Drug Store Stocks Fall

Mid-Afternoon Market Update: Dow Rises Over 100 Points; Progress Software Shares Spike Higher

Image credit: Mike Mozart, Flickr

The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Posted-In: contributor contributorsNews Technicals M&A Trading Ideas Best of Benzinga

 

Related Articles (AMZN + CVS)

View Comments and Join the Discussion!

3 Reasons Why Uniqure Could Overtake Hemophilia B Virus Gene Therapy

Ray Dalio's Bridgewater Associates Reorganizes With Partnership Model